Vitamin D regulation of osteoblast function

Vitamin D

Volumn , Issue , 2011, Pages 321-333

  Franceschi, Renny T ^a   Li, Yan ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884756649     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10017-4     Document Type: Chapter

References (111)

1. Franceschi R., Ge C., Xiao G., Roca H., Jiang D. Transcriptional regulation of osteoblasts. Ann. NY Acad. Sci. 2007, 1116:196-207.
2. Stricker S., Fundele R., Vortkamp A., Mundlos S. Role of Runx genes in chondrocyte differentiation. Dev. Biol. 2002, 245:95-108.
3. Robey P.G., Boskey A.L. The composition of bone. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 2008, 32-37. The American Society for Bone and Mineral Research, Washington, D.C. seventh ed. C.J. Rosen (Ed.).
4. Christoffersen J., Landis W.J. A contribution with review to the description of mineralization of bone and other calcified tissues in vivo. Anat. Rec. 1991, 230:435-450.
5. Huffman N.T., Keightley J.A., Chaoying C., Midura R.J., Lovitch D., Veno P.A., et al. Association of specific proteolytic processing of bone sialoprotein and bone acidic glycoprotein-75 with mineralization within biomineralization foci. J. Biol. Chem. 2007, 282:26002-26013.
6. Hunter G.K., Goldberg H.A. Nucleation of hydroxyapatite by bone sialoprotein. Proc. Natl. Acad. Sci. USA 1993, 90:8562-8565.
7. Malaval L., Wade-Gueye N.M., Boudiffa M., Fei J., Zirngibl R., Chen F., et al. Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J. Exp. Med. 2008, 205:1145-1153.
8. Ling Y., Rios H.F., Myers E.R., Lu Y., Feng J.Q., Boskey A.L. DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J. Bone Miner. Res. 2005, 20:2169-2177.
9. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 2006, 38:1310-1315.
10. Addison W.N., Nakano Y., Loisel T., Crine P., McKee M.D. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J. Bone Miner. Res. 2008, 23:1638-1649.
11. Bresler D., Bruder J., Mohnike K., Fraser W.D., Rowe P.S. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J. Endocrinol. 2004, 183:R1-9.
12. Martin A., David V., Laurence J.S., Schwarz P.M., Lafer E.M., Hedge A.M., et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 2008, 149:1757-1772.
13. Hessle L., Johnson K.A., Anderson H.C., Narisawa S., Sali A., Goding J.W., et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc. Natl. Acad. Sci. USA 2002, 99:9445-9449.
14. Addison W.N., Azari F., Sorensen E.S., Kaartinen M.T., McKee M.D. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J. Biol. Chem. 2007, 282:15872-15883.
15. Ducy P., Desbois C., Boyce B., Pinero G., Story B., Dunstan C., et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996, 382:448-452.
16. Ferron M., Hinoi E., Karsenty G., Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl. Acad. Sci. USA 2008, 105:5266-5270.
17. Franz-Odendaal T.A., Hall B.K., Witten P.E. Buried alive: how osteoblasts become osteocytes. Dev. Dyn. 2006, 235:176-190.
18. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 2000, 21:115-137.
19. Owen M. Cell population kinetics of an osteogenic tissue. I. J. Cell Biol. 1963, 19:19-32.
20. S.L. Dallas, L.F. Bonewald, Dynamics of the transition from osteoblast to osteocyte. Ann. NY Acad. Sci. 1192:437-443.
21. Bonewald L.F., Johnson M.L. Osteocytes, mechanosensing and Wnt signaling. Bone 2008, 42:606-615.
22. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 1999, 96:3540-3545.
23. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
24. Teitelbaum S.L., Ross F.P. Genetic regulation of osteoclast development and function. Nature Rev. Genet. 2003, 4:638-649.
25. Fu Q., Manolagas S.C., O'Brien C.A. Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol. Cell Biol. 2006, 26:6453-6468.
26. Kim S., Yamazaki M., Zella L.A., Shevde N.K., Pike J.W. Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol. Cell Biol. 2006, 26:6469-6486.
27. Galli C., Zella L.A., Fretz J.A., Fu Q., Pike J.W., Weinstein R.S., et al. Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology 2008, 149:146-153.
28. Takeda S., Yoshizawa T., Nagai Y., Yamato H., Fukumoto S., Sekine K., et al. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. Endocrinology 1999, 140:1005-1008.
29. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 1999, 20:345-357.
30. Corral D.A., Amling M., Priemel M., Loyer E., Fuchs S., Ducy P., et al. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc. Natl. Acad. Sci. USA 1998, 95:13835-13840.
31. Galli C., Fu Q., Wang W., Olsen B.R., Manolagas S.C., Jilka R.L., et al. Commitment to the osteoblast lineage is not required for RANKL gene expression. J. Biol. Chem. 2009, 284:12654-12662.
32. Feng J.Q., Ye L., Schiavi S. Do osteocytes contribute to phosphate homeostasis?. Curr. Opin. Nephrol. Hypertens. 2009, 18:285-291.
33. Tatsumi S., Ishii K., Amizuka N., Li M., Kobayashi T., Kohno K., et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007, 5:464-475.
34. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 2004, 19:429-435.
35. Larsson T., Marsell R., Schipani E., Ohlsson C., Ljunggren O., Tenenhouse H.S., et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004, 145:3087-3094.
36. Sitara D., Razzaque M.S., St-Arnaud R., Huang W., Taguchi T., Erben R.G., et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am. J. Pathol. 2006, 169:2161-2170.
37. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 2004, 113:561-568.
38. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
39. Razzaque M.S., Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol. Med. 2006, 12:298-305.
40. Haussler M., Haussler C., Whitfield G., Hsieh J.-C., Thompson P., Barthel T., et al. The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "fountain of youth" to mediate healthful aging. J. Steroid Biochem. Mol. Biol. 2010.
41. Quarles L. Endocrine functions of bone in mineral metabolism regulation. J. Clin. Invest. 2008, 118:3820-3828.
42. Robling A.G., Castillo A.B., Turner C.H. Biomechanical and molecular regulation of bone remodeling. Ann. Rev. Biomed. Engineer. 2006, 8:455-498.
43. Lanyon L.E., Rubin C.T. Static vs dynamic loads as an influence on bone remodelling. J. Biomech. 1984, 17:897-905.
44. Frost H.M. Vital biomechanics: proposed general concepts for skeletal adaptations to mechanical usage. Calcif. Tissue Int. 1988, 42:145-156.
45. Krahl H., Michaelis U., Pieper H.G., Quack G., Montag M. Stimulation of bone growth through sports. A radiologic investigation of the upper extremities in professional tennis players. Am. J. Sports Med. 1994, 22:751-757.
46. Leblanc A.D., Schneider V.S., Evans H.J., Engelbretson D.A., Krebs J.M. Bone mineral loss and recovery after 17 weeks of bed rest. J. Bone Miner. Res. 1990, 5:843-850.
47. Gleeson P.B., Protas E.J., LeBlanc A.D., Schneider V.S., Evans H.J. Effects of weight lifting on bone mineral density in premenopausal women. J. Bone Miner. Res. 1990, 5:153-158.
48. Rawlinson S., Pitsillides A., Lanyon L. Involvement of different ion channels in osteoblasts' and osteocytes early responses to mechanical strain. Bone 1996, 19:609-614.
49. Pitsillides A.A., Rawlinson S.C., Suswillo R.F., Bourrin S., Zaman G., Lanyon L.E. Mechanical strain-induced NO production by bone cells: a possible role in adaptive bone (re)modeling?. Faseb J. 1995, 9:1614-1622.
50. Fan X., Roy E., Zhu L., Murphy T.C., Ackert-Bicknell C., Hart C.M., et al. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. Endocrinology 2004, 145:751-759.
51. Jee W.S., Mori S., Li X.J., Chan S. Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. Bone 1990, 11:253-266.
52. Lin C., Jiang X., Dai Z., Guo X., Weng T., Wang J., et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J. Bone Miner. Res. 2009, 24:1651-1661.
53. Arnsdorf E.J., Tummala P., Jacobs C.R. Non-canonical Wnt signaling and N-cadherin related beta-catenin signaling play a role in mechanically induced osteogenic cell fate. PLoS ONE 4:e5388 2009.
54. Young S.R., Gerard-O'Riley R., Kim J.B., Pavalko F.M. Focal adhesion kinase is important for fluid shear stress-induced mechanotransduction in osteoblasts. J. Bone Miner. Res. 2009, 24:411-424.
55. Boutahar N., Guignandon A., Vico L., Lafage-Proust M.H. Mechanical strain on osteoblasts activates autophosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 tyrosine sites involved in ERK activation. J. Biol. Chem. 2004, 279:30588-30599.
56. Sen B., Styner M., Xie Z., Case N., Rubin C.T., Rubin J. Mechanical loading regulates NFATc1 and beta-catenin signaling through a GSK3beta control node. J. Biol. Chem. 2009, 284:34607-34617.
57. Li Y.J., Batra N.N., You L., Meier S.C., Coe I.A., Yellowley C.E., et al. Oscillatory fluid flow affects human marrow stromal cell proliferation and differentiation. J. Orthop. Res. 2004, 22:1283-1289.
58. Ma Y., Jee W.S., Yuan Z., Wei W., Chen H., Pun S., et al. Parathyroid hormone and mechanical usage have a synergistic effect in rat tibial diaphyseal cortical bone. J. Bone Miner. Res. 1999, 14:439-448.
59. Lee K., Jessop H., Suswillo R., Zaman G., Lanyon L. Endocrinology: bone adaptation requires oestrogen receptor-alpha. Nature 2003, 424:389.
60. Damien E., Price J.S., Lanyon L.E. The estrogen receptor's involvement in osteoblasts' adaptive response to mechanical strain. J. Bone Miner. Res. 1998, 13:1275-1282.
61. Gross T.S., Srinivasan S., Liu C.C., Clemens T.L., Bain S.D. Noninvasive loading of the murine tibia: an in vivo model for the study of mechanotransduction. J. Bone Miner. Res. 2002, 17:493-501.
62. Plotkin L.I., Mathov I., Aguirre J.I., Parfitt A.M., Manolagas S.C., Bellido T. Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases, and ERKs. Am. J. Physiol. Cell Physiol. 2005, 289:C633-643.
63. Aguirre J.I., Plotkin L.I., Gortazar A.R., Millan M.M., O'Brien C.A., Manolagas S.C., et al. A novel ligand-independent function of the estrogen receptor is essential for osteocyte and osteoblast mechanotransduction. J. Biol. Chem. 2007, 282:25501-25508.
64. Forwood M., Kelly W., Baldock P., Eisman J., Gardiner E. Mechanical sensitivity of the tibia is increased in mice over-expressing the vitamin D receptor in osteoblasts 2006, Combined meeting of the 3rd IOF Asia-Pacific Regional Conference on Osteoporosis and the 16th Annual Meeting of the ANZ Bone & Mineral Society, Port Douglas, Australia, 2006, p Abstract 26.
65. Rubin J., Murphy T.C., Fan X., Goldschmidt M., Taylor W.R. Activation of extracellular signal-regulated kinase is involved in mechanical strain inhibition of RANKL expression in bone stromal cells. J. Bone Miner. Res. 2002, 17:1452-1460.
66. Aubin J.E., Heersche J.N.M. Vitamin D and osteoblasts. Vitamin D 2005, 649-663. Elsevier Academic Press, Burlington, San Diego. second ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
67. Lian J., Stewart C., Puchacz E., Mackowiak S., Shalhoub V., Collart D., et al. Structure of the rat osteocalcin gene and regulation of vitamin D-dependent expression. Proc. Natl. Acad. Sci. USA 1989, 86:1143-1147.
68. Kerner S.A., Scott R.A., Pike J.W. Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3. Proc. Natl. Acad. Sci. USA 1989, 86:4455-4459.
69. Noda M., Vogel R.L., Craig A.M., Prahl J., DeLuca H.F., Denhardt D.T. Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. Proc. Natl. Acad. Sci. USA 1990, 87:9995-9999.
70. Kim R.H., Li J.J., Ogata Y., Yamauchi M., Freedman L.P., Sodek J. Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene. Biochem. J. 1996, 318:219-226.
71. Drissi H., Pouliot A., Koolloos C., Stein J.L., Lian J.B., Stein G.S., et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp. Cell Res. 2002, 274:323-333.
72. Paredes R., Arriagada G., Cruzat F., Villagra A., Olate J., Zaidi K., et al. Bone-specific transcription factor Runx2 interacts with the 1alpha,25-dihydroxyvitamin D3 receptor to up-regulate rat osteocalcin gene expression in osteoblastic cells. Mol. Cell Biol. 2004, 24:8847-8861.
73. Owen T.A., Aronow M.S., Barone L.M., Bettencourt B., Stein G.S., Lian J.B. Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures. Endocrinology 1991, 128:1496-1504.
74. 3-induced inhibition of bone nodule formation in long-term cultures of fetal rat calvaria cells. Endocrinology 1993, 132:61-66.
75. Bellows C.G., Reimers S.M., Heersche J.N. Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3. Cell Tissue Res. 1999, 297:249-259.
76. Beresford J.N., Gallagher J.A., Russell R.G. 1,25-Dihydroxyvitamin D3 and human bone-derived cells in vitro: effects on alkaline phosphatase, type I collagen and proliferation. Endocrinology 1986, 119:1776-1785.
77. Beresford J.N., Joyner C.J., Devlin C., Triffitt J.T. The effects of dexamethasone and 1,25-dihydroxyvitamin D3 on osteogenic differentiation of human marrow stromal cells in vitro. Arch. Oral. Biol. 1994, 39:941-947.
78. Zhang R., Ducy P., Karsenty G. 1,25-Dihydroxyvitamin D3 inhibits Osteocalcin expression in mouse through an indirect mechanism. J. Biol. Chem. 1997, 272:110-116.
79. Johnson J.A., Grande J.P., Roche P.C., Kumar R. Ontogeny of the 1,25-dihydroxyvitamin D3 receptor in fetal rat bone. J. Bone Miner. Res. 1996, 11:56-61.
80. Halloran B.P., Barthell E.N., DeLuca H.F. Vitamin D metabolism during pregnancy and lactation in the rat. Proc. Natl. Acad. Sci. USA 1979, 76:5549-5553.
81. Weinstein R.S., Underwood J.L., Hutson M.S., DeLuca H.F. Bone histomorphometry in vitamin D-deficient rats infused with calcium and phosphorus. Am. J. Physiol. 1984, 246:E499-505.
82. Panda D.K., Miao D., Bolivar I., Li J., Huo R., Hendy G.N., et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J. Biol. Chem. 2004, 279:16754-16766.
83. Gardiner E.M., Baldock P.A., Thomas G.P., Sims N.A., Henderson N.K., Hollis B., et al. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. Faseb J. 2000, 14:1908-1916.
84. Tanaka H., Seino Y. Direct action of 1,25-dihydroxyvitamin D on bone: VDRKO bone shows excessive bone formation in normal mineral condition. J. Steroid Biochem. Mol. Biol. 2004, 89-90:343-345.
85. Yamamoto Y., Yoshizawa T., Fukuda T., Kawano H., Nakamura T., Yamada T., et al. A genetic evidence of direct VDR function in osteoblasts-generation and analysis of osteoblast-specific VDRKO mice. J. Bone Miner. Res. 2004, 19:S26. Abstract.
86. Ge C., Xiao G., Jiang D., Franceschi R.T. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J. Cell Biol. 2007, 176:709-718.
87. Matsushita T., Chan Y.Y., Kawanami A., Balmes G., Landreth G.E., Murakami S. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol. Cell Biol. 2009, 29:5843-5857.
88. Ge C., Xiao G., Jiang D., Yang Q., Hatch N.E., Roca H., et al. Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor. J. Biol. Chem. 2009, 284:32533-32543.
89. Li Y., Ge C., Franceschi R. Differentiation-dependent association of phosphorylated extracellular signal-regulated kinase with the chromatin of osteoblast-related genes. J. Bone Miner. Res. 2009, 25:154-163.
90. Yang X., Matsuda K., Bialek P., Jacquot S., Masuoka H.C., Schinke T., et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 2004, 117:387-398.
91. Greenblatt M.B., Shim J.H., Zou W., Sitara D., Schweitzer M., Hu D., et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J. Clin. Invest. 2010, 120:2457-2473.
92. Shim J.H., Greenblatt M.B., Xie M., Schneider M.D., Zou W., Zhai B., et al. TAK1 is an essential regulator of BMP signalling in cartilage. EMBO J. 2009, 28:2028-2041.
93. Narayanan R., Sepulveda V.A., Falzon M., Weigel N.L. The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J. Biol. Chem. 2004, 279:47298-47310.
94. Ordonez-Moran P., Larriba M.J., Palmer H.G., Valero R.A., Barbachano A., Dunach M., et al. RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells. J. Cell Biol. 2008, 183:697-710.
95. Daniel C., Schroder O., Zahn N., Gaschott T., Stein J. p38 MAPK signaling pathway is involved in butyrate-induced vitamin D receptor expression. Biochem. Biophys. Res. Commun. 2004, 324:1220-1226.
96. Chae H.J., Jeong B.J., Ha M.S., Lee J.K., Byun J.O., Jung W.Y., et al. ERK MAP Kinase is required in 1,25(OH)2D3-induced differentiation in human osteoblasts. Immunopharmacol. Immunotoxicol. 2002, 24:31-41.
97. Meunier P., Aaron J., Edouard C., Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin. Orthop. 1971, 80:147-154.
98. McDonough A., Rosenthal R., Cao X., Saag K. The effect of thiazolidinediones on BMD and osteoporosis. Nature Clin. Pract. Endocrinol. Metab. 2008, 4:507-513.
99. Bodine P.V., Zhao W., Kharode Y.P., Bex F.J., Lambert A.J., Goad M.B., et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol. Endocrinol. 2004, 18:1222-1237.
100. Kawano Y., Kypta R. Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 2003, 116:2627-2634.
101. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
102. Hill T.P., Spater D., Taketo M.M., Birchmeier W., Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes [see comment]. Devel. Cell 2005, 8:727-738.
103. Rodda S.J., McMahon A.P. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 2006, 133:3231-3244.
104. Bennett C.N., Longo K.A., Wright W.S., Suva L.J., Lane T.F., Hankenson K.D., et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc. Natl. Acad. Sci. USA 2005, 102:3324-3329.
105. Glinka A., Wu W., Delius H., Monaghan A.P., Blumenstock C., Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998, 391:357-362.
106. Morvan F., Boulukos K., Clement-Lacroix P., Roman-Roman S., Suc-Royer I., Vayssiere B., et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res. 2006, 21:934-945.
107. Fretz J.A., Zella L.A., Kim S., Shevde N.K., Pike J.W. 1,25-Dihydroxyvitamin D3 regulates the expression of low-density lipoprotein receptor-related protein 5 via deoxyribonucleic acid sequence elements located downstream of the start site of transcription. Mol. Endocrinol. 2006, 20:2215-2230.
108. Cianferotti L., Demay M.B. VDR-mediated inhibition of DKK1 and SFRP2 suppresses adipogenic differentiation of murine bone marrow stromal cells. J. Cell Biochem. 2007, 101:80-88.
109. Sooy K., Sabbagh Y., Demay M.B. Osteoblasts lacking the vitamin D receptor display enhanced osteogenic potential in vitro. J. Cell Biochem. 2005, 94:81-87.
110. Wong K., Szeto F., Zhang W., Ye H., Kong J., Zhang Z., et al. Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E820-828.
111. Blumberg J.M., Tzameli I., Astapova I., Lam F.S., Flier J.S., Hollenberg A.N. Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells. J. Biol. Chem. 2006, 281:11205-11213.